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Abstract
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to be effective in
inhibiting colorectal cancer. Cyclooxygenase activity is thought to mediate, in part, this cancer
preventive effect. From observations made when cells that express cyclooxygenase activity were
treated with NSAIDs and known cancer preventive agents, I have postulated that arachidonic acid
(AA) release is associated with cancer prevention. In this study, the effects of NSAIDs on two cells
that do not express cycloxygenase activity are detailed.
Results: NSAIDs and several cancer preventive agents release AA from human colon cancer cells
(the HCT-15 cell line). The concentrations of NSAIDs required to release significant amounts of
AA from the HCT-15 cells are greater than those required to inhibit the lactacystin plus 12-0-
tetradecanoyl-13-acetate stimulated cyclooxygenase activity of rat liver cells. NSAIDs, tamoxifen
and simvastatin were found to hemolyze erythrocyte cells which also do not express
cyclooxygenase activity
Conclusion: The data demonstrate that AA release is independent of cyclooxygenase activity and
together with hemolysis suggest that intercalation of the plasma membrane by some NSAIDs and
cancer preventive agents, e.g. tamoxifen, mediates this release. A mechanism by which many of
these drugs affect several diverse biologic properties including deesterification of membrane
phospholipids by phospholipases to release AA is presented.
Background
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit
cyclooxygenase (COX) activity and the local production
of COX products that affect inflammation [1]. Neverthe-
less, the role of NSAIDs in several biologic pathways, at
high doses, has been questioned [2,3]. Some NSAIDs have
been shown to be cancer preventive [4,5]. The role of COX
in cancer prevention is suggested by the findings that COX
is overexpressed in tumors and that PGE2  levels are
increased in tumors. COX independent mechanisms for
cancer prevention have been shown by Rigas and collabo-
rators [6,7].
Based on the stimulation of AA release by several known
cancer preventive agents, e.g., tamoxifen, 9-cis-retinoic
acid, vitamin D3, statins, anti-oxidants found in green tea
and red wine, and peroxisome proliferator-activated
receptor ligands, I have proposed that AA release by cells
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is associated with cancer prevention [8-10]. Celecoxib, a
COX inhibitor, releases AA from rat liver, human colon
carcinoma, and rat glial cells in culture. Three of these
cells, rat liver (the C-9 cell line), the human colon cancer
(the HT-29 cell line) and rat glia (the C-6 cell line) express
COX [6,11,12]. The human colon carcinoma cell line
(HCT-15) does not produce prostaglandins (PG) when
treated with know stimulators of PG synthesis such as
mellitin, A-23187, fetal bovine serum or exogenous AA.
Nor do these cells express COX as measured by Northern
Blotting (6). In this report, evidence is presented that
NSAIDs and other cancer preventive agents release AA
from these HCT-15 cells.
Primary cultures of gastric mucosal cells undergo necrosis
as well as apoptosis after incubation with NSAIDs [13].
Thus, the effects of NSAIDs on the morphology of sheep
erythrocytes (SRBC), cells that also do not express COX
[14,15] were also examined using lysis as an indicator of
membrane perturbation and necrosis. Some NSAIDs as
well as tamoxifen and simvastatin hemolyze the washed
COX negative SRBC. Several of the NSAIDs are known to
intercalate the plasma membrane of cells [2,3].
Results
Preliminary experiments showed that the release of AA
from HCT-15 cells by 50 µM celecoxib was complete after
a 19 h incubation. The release of AA from these cells by
the COX inhibitors, celecoxib (50 µM) and NS398 (52
µM), is shown in Table 1. Celecoxib is more effective than
NS398 at comparable doses. The concentration depend-
encies of the release by celecoxib, sulindac sulfide,
indomethacin and ibuprofen are shown in Fig. 1.
Celecoxib is 40 to 100 times more effective than ibupro-
fen, and more effective than sulindac sulfide or indometh-
acin. In contrast to the observations presented in this
report, indomethacin, 200 µM, inhibited unstimulated AA
release from rabbit kidney slices 50% [16]. At 15 µM,
indomethacin did not inhibit AA release from perfused rab-
bit kidney after a 1 h incubation, but did inhibit its rate of
release after incubation with angiotensin II [16]. In our
studies, indomethacin stimulates AA release from unstim-
ulated human colon carcinoma (HCT-29 cells), rat liver
(C-9 cells), rat glial (C-6 cells) [8,9,17,18] and human
colon carcinoma (HCT-15 cells).
The dose-dependencies of AA release by tamoxifen and
simvastatin as well as those of thapsigargin and tetran-
drine are shown in Fig. 2. Thapsigargin is active even at 1.0
µM. It stimulates AA release from HT-29 cells [18] and
induces apoptosis in androgen-independent prostate can-
cer cell line [19]. Its analogs exhibit chemoprevention of
androgen-independent prostate cancer [20]. Thapsigargin
also induces apoptosis of human neuroblastoma, colon
cancer and thymocytes [21,22]. Tetrandrine stimulates AA
release from HT-29 cells [18] and is known to induce
apoptosis and is chemopreventive [23]. The dose-
response curve of tetrandrine is markedly more shallow
than those of the NSAIDs examined and suggests a differ-
ent mechanism of AA release.
The insolubility of several of these drugs precludes gener-
ation of extensive dose-response curves at high concentra-
tions. At concentrations at which they were soluble, they
release a significant amount of AA (Table 2). The concen-
trations of NSAIDs required for release of AA are greater
than those required to inhibit COX as measured by PGI2
production of lactacystin plus TPA stimulated COX posi-
tive rat liver cells (data not shown). Indomethacin, 50 µM,
significantly stimulates AA release from the HCT-15 cells,
but 0.003 µM, 4 orders of magnitude less, is required to
inhibit 50 % of PGI2 produced by different cells (the COX
positive C-9 rat liver cells) stimulated by lactacystin plus
TPA treatment. COX-inhibition depends on several fac-
tors including time of incubation, cellular source of the
COX, stimulator of the COX (endotoxin, A-23187, TPA,
etc.), subcellular location of the COX, concentration of
substrate and the degree of COX-PLA2 coupling. For exam-
ple, the IC50 for COX-2 inhibition of PG production by
indomethacin when treated with endotoxin-stimulated
broken macrophage was 1.1 µM, but when assayed with
purified enzyme, it was 14 µM [24].
A low concentration of SRBC (6.5 × 107 cells/ml) was used
to quantitate hemolysis [25] after incubation of these
Release of AA from HCT-15 cells by increasing quantities of  celecoxib (O), sulindac sulfide (), indomethacin () or ibu- profen () Figure 1
Release of AA from HCT-15 cells by increasing quantities of 
celecoxib (O), sulindac sulfide (), indomethacin () or ibu-
profen (). The HCT-15 cells were incubated with the 
NSAIDs for 19 h. Centrifuged culture fluids (200 µl) were 
counted for radioactivity.BMC Pharmacology 2006, 6:7 http://www.biomedcentral.com/1471-2210/6/7
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COX negative cells with several NSAIDs, tamoxifen or
simvastatin. Hemolysis by celecoxib (80 µM) and
tamoxifen (20 µM and 40 µM) is shown in Table 3. The
concentration dependencies for hemolysis by celecoxib,
sulindac sulfide, indomethacin and ibuprofen are shown
in Fig. 3. As with AA release (Fig. 1), celecoxib is the most
effective. Treatment of cells with tamoxifen and simvasta-
tin also hemolyze the SRBC (Fig. 4). Tetrandrine or thap-
sigargin, even when tested at 1 mM and 100 µM
respectively do not lyse the SRBC (data not shown), sug-
gesting that the mechanisms of AA release by tetrandrine
and thapsigargin differs from that of NSAIDs, tamoxifen
or simvastatin.
When the effect of cell density on hemolysis was tested
with celecoxib, tamoxifen or simvastatin, the number of
cells lysed was higher at the lower cell densities (data not
shown). Under the experimental conditions described, an
approximate number of molecules of drug required to
hemolyze 2.5 × 107 SRBC was calculated (Table 4). These
values may be grossly overestimated since binding to the
1 % bovine serum albumin (BSA) in the vehicle was not
considered.
Discussion
In contrast to HT-29 cells which are known to be COX
dependent, HCT-15 cells do not respond to known stim-
ulants of COX activity, such as mellitin, A-23187, fetal
bovine serum or even exogenous AA [6]. Nor are tran-
scripts of mRNA from both COX-1 and COX-2 genes
detected in these HCT-15 cells [6]. When measured by
confocal microscopy, however, COX is detected in these
HCT-15 cells [26]. A study of AA release by the COX-null
embryo fibroblasts described by Zhang et al [27] would be
informative and provide another COX negative cell for
study. Although erythrocytes, are COX negative [14,15],
they may express lipoxygenase (LOX). Sulindac sulfide
and indomethacin stimulate AA release from the colorec-
tal cancer cell lines, SW480 and HCT-116. It is the AA
release per se that leads to apoptosis [28]. Chan et al [28]
have suggested that inhibition of COX is a mechanism of
action of NSAIDs. By inhibiting COX, more AA is made
available as substrate for sphingomyelin to ceramide con-
version. I have proposed that the release of AA is associ-
ated with cancer prevention [8-10,17,18]. The AA release
was observed from COX positive rat liver (C-9), COX pos-
itive human colon cancer (HT-29) and COX positive rat
glioma (C-6) cells. Growth of COX negative and COX
positive cells is inhibited and their progression to apopto-
sis is increased by NSAIDs [6,7]. In cells different than
those cited above, others have demonstrated COX inde-
pendence for NSAID actions [reviewed in [29,30]].
Red blood cells do not express COX activity [14,15], yet
incorporate AA into their phospholipids. After a 5 min
incubation with the Ca2+ ionophore, A-23187, 26 % the
Table 1: Release of AA from HCT-15 cells by celecoxib (50 µM) 
and NS-398 (52 µM). HCT-15 cells, 0.3 to 1.0 × 105/dish, were 
incubated with the celecoxib, NS-398 or control for 19 h at 37°C. 
After centrifugation, culture fluids (200 µl) were counted for 
radioactivity.
Drug tested cpm/200 µl AA Release %
None 706 2.7
947 3.6
(Control MEM/BSA) 943 3.6
799 3.1
793 3.0
m = 838 ± 46.8 m = 3.2 ± 0.18
Celecoxib (50 µM) 3740 14.4
4441 17.1
3851 14.8
4166 16.0
4413 16.9
m = 4122 ± 143 m = 15.8 ± 0.54
NS398 (52 µM) 1140 4.4
1328 5.1
1223 4.7
1249 4.8
1186 4.6
m = 1225 ± 32 m = 4.7 ± 0.12
Input = 32,880 cpm/200 µl
Cells = 26,045 cpm/200 µl
Uptake = 79%
Release of AA from HCT-15 cells by various concentrations  of thapsigargin (), tamoxifen (), simvastatin (❍ ) and  tetrandrine (♦) Figure 2
Release of AA from HCT-15 cells by various concentrations 
of thapsigargin (), tamoxifen (), simvastatin (❍ ) and 
tetrandrine (). The experiment was done with triplicate 
dishes. Incubation conditions were similar to those described 
in Fig. 1.BMC Pharmacology 2006, 6:7 http://www.biomedcentral.com/1471-2210/6/7
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AA is found unesterified when analyzed by high pressure
liquid and thin layer chromatography [14]. In the present
study, hemolysis is observed after a 19 h incubation of
SRBC with NSAIDs, tamoxifen or simvastatin. Celecoxib
is about 30 times more effective than ibuprofen (Fig. 3
and Table 4). The relative activities of celecoxib, rofecoxib
and valdecoxib for the necrotic stage of the actions of
NSAIDs, as measured by hemolysis of SRBC, may be asso-
ciated with an unwanted side reaction. The hemolysis sug-
gests a mechanism proposed much earlier [2,3] for the
effects of NSAIDs on a variety of biological pathways,
namely, perturbation of the cell membranes and disrup-
tion of normal signaling pathways (Fig. 5). The deesterifi-
cation of phospholipids could lead to altered signaling. It
is not restricted to NSAIDs. Even at high concentrations,
AA release is stimulated by tamoxifen. It is independent of
estrogen synthesis [9]. The stimulation of AA release by
simvastatin is independent of cholesterol synthesis [10].
Simvastatin also hemolyzes SRBC (Fig. 4). The significant
correlation between high doses of statins and bone frac-
tures [31] may reflect intercolated cell membranes of cells
relevant to bone integrity, i.e. the biological response to
high doses of such drugs may depend on the function of
the target cell.
COX inhibitors leading to decreased AA metabolism may
be the primary pathway for combating pain. The perturba-
tion of the membrane and the accompanying changes in
signaling may be responsible for many of their other bio-
logical effects, including cancer chemoprevention, reduc-
tion of amyloid production in Alzheimer disease [32] and
possibly even production of lesions in the gastric mucosa
[33]. It would be of interest to assess epidemiologically
other conditions that may be affected by exposure to high
doses of NSAIDs, e.g., cardiotoxicity. The effects of these
agents do not appear to be selective to cancer cells.
Table 3: Hemolysis of 6.5 × 107(2.6 x107 /ml) SRBC by celecoxib 
(80 µM) and tamoxifen (20 and 40 µM). The SRBC (2.5 ml) were 
incubated in a shaking bath for 19 h at 37°C. The cells were 
centrifuged and the supernates analyzed for oxyhaemoglobin by 
absorption at 413 nm. Complete hemolysis was calculated from 
the absorption of the H2O lysate of the centrifuged cells of the 
controls. Controls for absorption at 413 nm of the reagents in 
the PBS/BSA vehicle as well as controls that contained known 
amounts of SRBC lysate were used to measure the effects of 
NSAIDs, if any, on oxyhemoglobin absorption.
Reagent Hemolysis * % Absorbance 413 nm
H2O 100 2.442
2.439
2.423
2.427
m = 2.433 ± 0.01
Celecoxib (80 µM) 29 0.799
0.912
0.988
0.635
m = 0.834 ± 0.077
Tamoxifen (40 µM) 96 2.293
2.349
2.396
2.352
m = 2.348 ± 0.02
Tamoxifen (20 µM) 29 0.789
0.844
1.044
0.701
m = 0.845 ± 0.07
PBS/BSA (Control) 0 0.193
0.214
0.186
0.134
m = 0.182 ± 0.017
* = % Hemolysis of 6.5 × 107 SRBC (2.6 × 107 SRBC/ml).
Table 2: Release of AA from HCT-15 cells by NSAIDs and 
several cancer preventive agents. Such experiments were 
performed several times with similar results. The experimental 
conditions are similar to those given in Table 1.
Drug tested Concentration AA Release *, †
MEM/BSA (control) 0 3.2 ± 0.09 (5)
NaCl 10 mM 3.3 ± 0.12 (3)
A) NSAIDs **
Acetylsalicylic acid 10 mM 3.6 ± 0.13 (5)
Diflunisac 460 µM 6.7 ± 0.28 (3)
Naproxine 3 mM 4.1 ± 0.29 (3)
Na salicylate 10 mM 5.6 ± 0.18 (5)
NS398 52 µM 4.7 ± 0.35 (5)
Piroxicam 10 mM 4.2 ± 0.33 (5)
Rofecoxib, (Vioxx®) *** 100 µM 4.2 ± 0.41 (3)
Valdecoxib, (Bextra®)*** 178 µM 6.2 ± 0.44 (3)
B) Drugs that are not NSAIDs – several are cancer 
preventative.
Acetaminophen 10 mM 4.0 ± 0.11 (5)
(-)-Epigallocatechin gallate 224 µM 4.3 ± 0.19 (3)
17 β-Estradiol 100 µM 4.5 ± 0.48 (3)
GW-7845 50 µM 9.5 ± 0.39 (3)
Raloxifene 50 µM 10.9 ± 0.47 (4)
Raloxifene 100 µM 13.3 ± 0.64 (3)
9-cis-retinoic acid 83 µM 7.5 ± 0.36 (3)
Resveritrol 100 µM 5.0 ± 0.29 (3)
* = All values except for NaCl, are statistically significant.
** = Solubility of drugs in MEM/BSA does not permit generation of 
dose-response curves.
*** = DMSO extracts of tablet – 100 % yield assumed.
† = These values are from one experiment. Each drug and controls 
were examined at least two times. In each experiment these drugs 
gave statistically significant stimulation vs MEM/BSA.BMC Pharmacology 2006, 6:7 http://www.biomedcentral.com/1471-2210/6/7
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The numerous findings of overexpression of COX-2 and
elevated PGE2 levels in cancer as well as the genetic evi-
dence [reviewed in [29,30]] have lead to the concept that
COX-2 is a primary target for cancer prevention. Alterna-
tively, the effects on cancer prevention observed with
NSAIDs and some other agents may result from the stim-
ulation of AA release followed by the altered downstream
signaling. Lypooxygenase (LOX) and LOX products (5-
LOX and 12-LOX) are up-regulated in human pancreatic
cancer. Inhibitors of LOX induce apoptosis in these
human pancreatic cell lines [reviewed in [29]]. Since LOX
activity was not examined in the HCT-15 cells, the possi-
bility that LOX is a target for the NSAIDs cannot be ruled
out. LOX activity is present in the SRBC undergoing
hemolysis but the effect of NSAIDs on the production of
LOX products was not studied.
The majority of the compounds tested for release of AA
from cells in culture are effective at concentrations of 50
µM or greater. Such concentrations are significantly higher
than those found in patients receiving i.e., indomethacin,
20 µM, based on serum levels. However, based only on
serum levels, estimations of ligand concentration effective
on the target cells can be misleading. For example, sulin-
dac sulfide levels may be 20-fold higher in colonic epithe-
lial cells of guinea pigs than in serum [34]. In addition,
comparison of the effects of drug concentrations in cell
cultures and in humans is subject to inherent experimen-
tal differences. High doses of NSAIDs are used in cell cul-
ture experiments while low doses may be effective in man.
In cell culture experiments the time of incubation of cells
with NSAIDs is of necessity relatively short whereas in
patients, the effects are usually observed after much longer
periods of time of exposure, sometimes years. The physi-
ological relevance of the high levels of NSAIDs found in
vitro has been addressed in recent reviews [29,30].
Conclusion
A cell that does not express COX activity (HCT-15)
releases AA when incubated with NSAIDs and cancer pre-
ventive agents. COX negative SRBC also undergo lysis
when incubated with NSAIDs, tamoxifen or simvastatin
suggesting that the mechanism of action of these drugs
involves their intercalation of the membrane and disrup-
tion of signaling messages.
Methods
The human colon carcinoma (HCT-15 cell line) and the
rat liver (C-9 cell line) were purchased from the American
Type Culture Collection (Manassas, VA, USA). They were
maintained in Eagle's minimum essential medium
(MEM) supplemented with 10% fetal bovine serum. [3H]
Table 4: Number of molecules of drug per erythrocyte required 
for hemolysis of 2.6 × 107SRBC.
Drug µM required for lysis of 2.6 × 
107/ml SRBC.
Molecules per 
erythrocyte
Tamoxifen 31 µM7 . 3  ×  1 0 8
Simvastatin 49 µM1 . 1  ×  1 0 9
Celecoxib 95 µM2 . 2  ×  1 0 9
Sulindac sulfide 178 µM4 . 1  ×  1 0 9
Indomethacin 1.5 mM 3.5 × 1010
Ibuprofen 2.75 mM 6.4 × 1010
* = % Hemolysis of 6.5 × 107 SRBC (2.6 × 107 SRBC/ml).
Hemolysis of 6.5 × 107 SRBC (2.6 × 107/ml) by various con- centrations of tamoxifen () and simvastatin () Figure 4
Hemolysis of 6.5 × 107 SRBC (2.6 × 107/ml) by various con-
centrations of tamoxifen () and simvastatin (). Experi-
mental and controls are described in Table 4.
Hemolysis of 6.5 × 107 SRBC (2.6 × 107/ml) by various con- centrations of celecoxib (), sulindac sulfide (), indometh- acin (❍ ) and ibuprofen () Figure 3
Hemolysis of 6.5 × 107 SRBC (2.6 × 107/ml) by various con-
centrations of celecoxib (), sulindac sulfide (), indomethacin 
(❍ ) and ibuprofen (). Experimental conditions were similar 
to those described in Table 4.BMC Pharmacology 2006, 6:7 http://www.biomedcentral.com/1471-2210/6/7
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AA (91.8 Ci/mmol) was obtained from NEN Life Science
Products, Inc. (Boston, MA, USA). The washed SRBC were
purchased from Lampire Biological Laboratories (Pipers-
ville, PA, USA). All other reagents were from Sigma Chem-
ical Co. (St. Louis, MO, USA) or Calbiochem, (San Diego,
CA, USA).
Two days prior to experiments, the HCT-15 or C-9 cells
were treated with 0.25% trypsin-EDTA and, after addition
of minimal essential media (MEM) containing 10% fetal
calf serum, the floating cells were seeded on to 35 mm cul-
ture dishes. The plating densities varied from 0.1 to 0.5 ×
105 cells/35 mm dish. The freshly seeded cultures were
incubated for 24 h to allow for cell attachment. After
decantation of MEM containing the fetal bovine serum,
1.0 ml fresh MEM containing 10% fetal bovine serum and
[3H] AA (0.2 µCi/ml) was added and the cells incubated
for another 24 h. The cells were washed 4 times with MEM
and incubated for 19 h with 1.0 ml of MEM containing
1.0 mg BSA/ml (MEM/BSA) and different concentrations
of each compound. The culture fluids were then decanted,
centrifuged at 2000 x g for 10 min, and 200 µl of the
supernate counted for radioactivity. Radioactivity recov-
ered in the washes before the incubation was compared to
input radioactivity to calculate the % radioactivity incor-
porated into the cells. The MEM/BSA values are the con-
trol values. The [3H] AA release is presented as a
percentage of the radioactivity incorporated by the cells.
In 56 experiments, the average release of AA from HCT-15
cells in the presence of MEM/BSA was 3.2 ± 38 %. For all
data presented, values are normalized to an MEM/BSA
value of 3.2%. Three to five culture dishes were used for
each experimental point. The data are expressed as mean
values ± SEM. The data were evaluated statistically by the
unpaired Student's t-test. A P value < 0.05 was considered
significant.
For measuring the effect of NSAIDs on PGI2 production,
the C-9 cells were incubated for an additional 24 h with
MEM plus 10% fetal bovine serum (minus [3H] AA). The
cells were washed three times with MEM and incubated
with 5.4 µM lactacystin plus 17 mM TPA in MEM/BSA in
the presence of various concentrations of NSAIDs for 6 h.
The culture fluids were centrifuged and the supernates
analyzed for 6-keto-PGF1α, the stable hydrolytic product
of PGI2, by radioimmunoassay [35].
For the hemolysis studies, 100 µl of the SRBC suspension
were washed twice with about 15 ml of phosphate buff-
ered saline (pH 7.3) containing BSA (1 mg/ml) (PBS/
BSA). The washed cells were resuspended in 50 ml PBS/
BSA and 2.5 ml (2.6 × 107/ml) were incubated with vary-
ing concentrations of the reagents for 19 h at 37°C. The
reaction mixtures were centrifuged and the oxyhaemo-
globin measured by absorption at 413 nm. The pellets
containing the intact erythrocytes were lysed with 2.5 ml
H2O and they too measured for absorption. To determine
the number of cells in the experiment, 1 ml of the SRBC
suspension was diluted to 15 ml with H2O and the lysate
measured for absorption. Controls were performed by
incubation of each test reagent in the vehicle alone and
measured for absorption in the presence and absence of
oxyhaemoglobin. Only sulindac sulfide and indometh-
acin, at the concentrations used, absorbed at 413 nm. Ibu-
profen, at concentrations above 3.5 mM, reduced
oxyhaemoglobin absorption.
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